glp-1 obesity drug news october 2025 Novo, Lilly weight-loss drugs should be first option treatments, European doctors say The GLP-1 revolution: What UAB

Description

Kotwal S, Perkovic E, Perkovic V (2024) Combination therapy with kidney protective therapies: optimizing the benefits

Duration of Benefit The health benefits of GLP-1R agonists are most pronounced within the first year of treatment, with significant improvements in glycated hemoglobin (HbA1c), body mass index (BMI), and cardiovascular outcomes

PubMed Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response

I encourage you to try it yourself, especially if you are in medical affairs, R&D, or clinical education

The performance of companies within the fund benefits from the clinical and commercial success of obesity drugs, which is an uncorrelated source of return in the market